Allogene Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Allogene Therapeutics Inc
TickerALLO
CIK #0001737287
CUSIP019770106
SectorLife Sciences - Biological Products, (No Disgnostic Substances)
Address210 East Grand Avenue, South San Francisco, CA 94080
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Allogene Therapeutics Inc 2018-04-19 411.8 M Exemption: 506(b) · Duration: One year or less · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001737287] 10-K
[0001737287] 10-Q
[0001737287] 3
[0001737287] 4
[0001737287] 5
[0001737287] 8-K
[0001737287] D
[0001737287] SC 13D
[0001737287] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Frazier Life Sciences Public Fund LP Allogene Therapeutics Inc [2026-04-23] 0.0
Chang David D Allogene Therapeutics Inc [2026-02-13] 0.0
Citadel Advisors LLC Allogene Therapeutics Inc [2025-07-16] 0.0
Capital World Investors Allogene Therapeutics Inc [2025-05-13] 0.0
Lynx1 Capital Management LP Allogene Therapeutics Inc [2025-02-14] 0.0
Vanguard Group Inc Allogene Therapeutics Inc [2024-11-04] 3.98
FMR LLC Allogene Therapeutics Inc [2023-07-10] 0.0
Chang David D Allogene Therapeutics Inc [2023-02-13] 5.7
Vanguard Group Inc Allogene Therapeutics Inc [2023-02-09] 5.04
BlackRock Inc Allogene Therapeutics Inc [2023-02-03] 6.2
State Street Corp Allogene Therapeutics Inc [2023-02-03] 6.36
Capital International Investors Allogene Therapeutics Inc [2021-02-16] 5.5
Capital Research Global Investors Allogene Therapeutics Inc [2020-02-14] 5.3
Gilead Sciences Inc Allogene Therapeutics Inc [2019-02-13] 6.2
Belldegrun Arie Allogene Therapeutics Inc [2019-02-13] 0.8
Seaview Trust Allogene Therapeutics Inc [2019-02-13] 7.0
TPG Group Holdings SBS Advisors Inc Allogene Therapeutics Inc [2018-10-25] 19.6
Pfizer Inc Allogene Therapeutics Inc [2018-10-22] 18.7
Form 3/4/5 Filer 2011 - 2026
Allogene Therapeutics Inc
Roberts Zachary
Humer Franz B
Sato Vicki L
Kazam Joshua A
Barrett Elizabeth A
Messemer Deborah M
Mayo Stephen
Witte Owen N
Yoshiyama Annie
Beneski Benjamin Machinas
Chang David D
Belldegrun Arie
Douglas Earl Martin
Parker Geoffrey M
Moore Timothy L
Chen Yinlin Jack
Smith Lillian
Moore Alison
Schmidt Eric Thomas
Bhavnagri Veer
Amado Rafael
PF Equity Holdings 2 BV
TPG GP A LLC
Winkelried Jon
TPG Group Holdings SBS Advisors Inc
Bonderman David
Coulter James G
Pfizer Inc
Deyoung John A
Sisitsky Todd Benjamin
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Beneski Benjamin Machinas
Common Stock
2026-03-16 Sell 4,835 $2.47 11,942
Chang David D
Common Stock
2026-03-16 Sell 47,763 $2.47 117,975
Beneski Benjamin Machinas
Common Stock
2026-03-02 Sell 7,132 $2.60 18,543
Parker Geoffrey M
Common Stock
2026-02-02 Sell 24,001 $1.76 42,242
Chang David D
Restricted Stock Unit · derivative
2026-02-02 Grant 392,586 $0.00
Chang David D
Stock Option (Right to buy) · derivative
2026-02-02 Grant 1,387,931 $0.00
Belldegrun Arie
Restricted Stock Unit · derivative
2026-02-02 Grant 263,033 $0.00
Roberts Zachary
Stock Option (Right to buy) · derivative
2026-02-02 Grant 718,763 $0.00
Yoshiyama Annie
Common Stock
2026-02-02 Sell 4,167 $1.72 7,167
Yoshiyama Annie
Stock Option (Right to buy) · derivative
2026-02-02 Grant 179,691 $0.00
Roberts Zachary
Restricted Stock Unit · derivative
2026-02-02 Grant 203,307 $0.00
Beneski Benjamin Machinas
Stock Option (Right to buy) · derivative
2026-02-02 Grant 373,757 $0.00
Douglas Earl Martin
Stock Option (Right to buy) · derivative
2026-02-02 Grant 539,072 $0.00
Beneski Benjamin Machinas
Common Stock
2026-02-02 Sell 7,549 $1.73 13,060
Yoshiyama Annie
Restricted Stock Unit · derivative
2026-02-02 Grant 50,827 $0.00
Douglas Earl Martin
Restricted Stock Unit · derivative
2026-02-02 Grant 152,480 $0.00
Parker Geoffrey M
Stock Option (Right to buy) · derivative
2026-02-02 Grant 539,072 $0.00
Douglas Earl Martin
Common Stock
2026-02-02 Sell 22,900 $1.76 40,304
Roberts Zachary
Common Stock
2026-02-02 Sell 35,700 $1.77 63,189
Belldegrun Arie
Stock Option (Right to buy) · derivative
2026-02-02 Grant 929,913 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 208 178,937,349
2025-12-31 172 163,054,393
2025-09-30 170 162,921,936
2025-06-30 158 184,884,184
2025-03-31 172 197,439,052
2024-12-31 176 184,408,073
2024-09-30 157 162,262,985
2024-06-30 175 163,840,758
2024-03-31 162 136,803,524
2023-12-31 171 128,339,027
2023-09-30 155 128,064,477
2023-06-30 172 128,169,801
Form 13F Holdings
Firm Period DFND Voting Shares
Hennion & Walsh Asset Management Inc [2026-06-30] SOLE 722,928 722,928
Harold Davidson & Associates Inc [2026-06-30] SOLE 281,522 281,522
Wealth Enhancement Advisory Services LLC [2026-06-30] SOLE 3,391 68,551
CFG Wealth Management Services Inc [2026-06-30] SOLE 0 40,000
Westmount Partners LLC [2026-06-30] SOLE 36,000 36,000
Gamma Investing LLC [2026-06-30] DFND 15,325 15,325
Ballentine Partners LLC [2026-06-30] OTR 0 11,131
Farther Finance Advisors LLC [2026-06-30] SOLE 0 2,099
Fortitude Family Office LLC [2026-06-30] SOLE 1,044 1,044
IFP Advisors LLC [2026-06-30] SOLE 593 593
Physician Wealth Advisors Inc [2026-06-30] SOLE 0 450
True Wealth Design LLC [2026-06-30] SOLE 0 377
Arcadia Investment Advisors LLC [2026-06-30] SOLE 0 20
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com